iBio (IBIO) Competitors $0.57 -0.01 (-2.25%) Closing price 04:00 PM EasternExtended Trading$0.58 +0.00 (+0.51%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IBIO vs. ACRV, GRCE, EGRX, COEP, LVTX, SLGL, STTK, OVID, HYPD, and ENLVShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Acrivon Therapeutics (ACRV), Grace Therapeutics (GRCE), Eagle Pharmaceuticals (EGRX), Coeptis Therapeutics (COEP), LAVA Therapeutics (LVTX), Sol-Gel Technologies (SLGL), Shattuck Labs (STTK), Ovid Therapeutics (OVID), Hyperion DeFi (HYPD), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors Acrivon Therapeutics Grace Therapeutics Eagle Pharmaceuticals Coeptis Therapeutics LAVA Therapeutics Sol-Gel Technologies Shattuck Labs Ovid Therapeutics Hyperion DeFi Enlivex Therapeutics Acrivon Therapeutics (NASDAQ:ACRV) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings. Which has more risk & volatility, ACRV or IBIO? Acrivon Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, iBio has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Do insiders & institutionals have more ownership in ACRV or IBIO? 71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 0.6% of iBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor ACRV or IBIO? In the previous week, Acrivon Therapeutics had 3 more articles in the media than iBio. MarketBeat recorded 3 mentions for Acrivon Therapeutics and 0 mentions for iBio. Acrivon Therapeutics' average media sentiment score of 0.62 beat iBio's score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Acrivon Therapeutics Positive iBio Neutral Do analysts rate ACRV or IBIO? Acrivon Therapeutics currently has a consensus target price of $17.71, suggesting a potential upside of 1,317.14%. iBio has a consensus target price of $5.00, suggesting a potential upside of 772.45%. Given Acrivon Therapeutics' higher possible upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ACRV or IBIO more profitable? Acrivon Therapeutics' return on equity of -44.66% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -44.66% -40.94% iBio N/A -73.15%-45.51% Which has higher earnings & valuation, ACRV or IBIO? iBio has higher revenue and earnings than Acrivon Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.22-0.56iBio$375K25.25-$24.91MN/AN/A SummaryAcrivon Therapeutics beats iBio on 10 of the 12 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$9.47M$830.25M$5.50B$20.66BDividend YieldN/A4.84%4.64%3.66%P/E RatioN/A1.1730.3928.37Price / Sales25.2525.76447.5260.19Price / CashN/A19.5637.7222.93Price / Book0.416.538.305.38Net Income-$24.91M-$4.39M$3.26B$994.60M7 Day Performance-7.99%1.22%0.91%1.50%1 Month Performance-29.65%-0.20%3.66%0.49%1 Year Performance-63.73%22.91%46.29%18.07% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.1741 of 5 stars$0.57-2.3%$5.00+772.4%-62.4%$9.47M$375K0.00100ACRVAcrivon Therapeutics3.2752 of 5 stars$1.33+5.6%$17.71+1,231.9%-84.0%$41.70MN/A-0.6058News CoverageGRCEGrace Therapeutics2.8195 of 5 stars$3.00+4.5%$12.00+300.0%N/A$41.49MN/A-3.37N/ANews CoverageEarnings ReportGap UpHigh Trading VolumeEGRXEagle PharmaceuticalsN/A$3.19-13.6%N/A-21.8%$41.43M$257.55M0.00100Gap DownCOEPCoeptis Therapeutics0.6139 of 5 stars$11.55+7.7%N/A+173.8%$40.54MN/A-1.992LVTXLAVA Therapeutics1.8523 of 5 stars$1.47+3.5%$3.17+115.4%-14.1%$38.67M$4.99M-1.4160Upcoming EarningsHigh Trading VolumeSLGLSol-Gel Technologies2.9294 of 5 stars$13.42+3.2%$40.00+198.1%+337.0%$37.44M$11.54M-2.8650Upcoming EarningsGap UpSTTKShattuck Labs3.4927 of 5 stars$0.74+1.5%$7.50+909.8%-75.7%$35.58M$4.61M-0.53100Upcoming EarningsOVIDOvid Therapeutics4.6387 of 5 stars$0.50-0.7%$3.13+529.4%-38.0%$35.31M$570K-1.4260News CoverageGap UpHYPDHyperion DeFi0.2871 of 5 stars$6.29-11.2%$2.00-68.2%-88.6%$35.24M$67.06K-0.1140Gap UpENLVEnlivex Therapeutics2.744 of 5 stars$1.48+2.1%$10.00+575.7%+17.6%$35.00MN/A-2.2470Gap UpHigh Trading Volume Related Companies and Tools Related Companies ACRV Alternatives GRCE Alternatives EGRX Alternatives COEP Alternatives LVTX Alternatives SLGL Alternatives STTK Alternatives OVID Alternatives HYPD Alternatives ENLV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredSell these stocks now—what to buy insteadSell these stocks now—Here’s what to buy instead Wall Street legend Marc Chaikin says you must know these 3...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.